Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Randomized Controlled Multicenter Trial of Exercise Training in Pulmonary Hypertension in European Countries (EU-TRAIN-01)

17 de dezembro de 2019 atualizado por: Prof. Dr. med. Ekkehard Gruenig, Heidelberg University

Implementation and Effect of Exercise and Respiratory Training on 6-minute Walking Distance in Patients With Severe Chronic Pulmonary Hypertension: a Randomized Controlled Multicenter Trial in European Countries

Chronic pulmonary hypertension (PH) is associated with impaired exercise capacity, quality of life and right ventricular function. The disease is characterized by an increase of pulmonary vascular resistance and pulmonary arterial pressure, leading to right heart insufficiency.

Despite optimized combination-medical therapy most patients remain symptomatic, have reduced exercise capacity, quality of life and reduced survival rates, with an annual mortality rate of approximately 5 -15 % or even higher.

Previous training studies have suggested that exercise training as add-on to medical treatment is highly effective improving exercise capacity, quality of life and symptoms.

The current guidelines recommend exercise training only in specialized centres including both PH and rehabilitation specialists who are experienced in exercise training of severely compromised patients.

A specialized PH-training program has been performed in Heidelberg since 2003 including >1200 patients with various forms of chronic PH. The exercise training program is performed in a special setting with an in-hospital start of the rehabilitation program. It is characterized by a low-dose closely supervised exercise training in small groups with additional psychological support and mental training.

This training program for patients with PH will be implemented in European centers to add exercise training to the existing PH therapies. The effect of the training on physical exercise capacity will be assessed by 6-minute walking distance (6-MWD). Further clinical parameters will be assessed to evaluate the effect on exercise capacity, quality of life and symptoms.

The aim of this study is to guide European PH-centers to become specialized centers for training in PH.

126 patients will be included, who either receive exercise training or continue their daily sedentary life style (1:1 randomization) for 15 weeks.

As inpatient settings are not available in all healthcare systems the training program will be adapted from the specific training program for PH patients developed in Heidelberg to a procedure, which is feasible in the local participating centres. Another objective of this study is to assess if the particular adopted training program specified for each participating centre and country is still safe and effective.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

Pulmonary hypertension (PH) is defined as a mean pulmonary arterial pressure ≥25 mmHg. PH is often diagnosed at an advanced stage (WHO functional class III-IV) with a massive increase of the mean pulmonary arterial pressure. A crucial parameter determining the symptoms and prognosis of the patients is the cardiac reserve. This parameter is defined by the pulmonary vascular resistance and the right ventricular adaptation. Severe PH is characterized by a decreased cardiac output at rest, an increased afterload and consecutive cor pulmonale.

Within the last years there has been a huge progress in the scientific fields of genetics, pathogenesis, pathophysiology and therapy of PH. This has also been documented in the PH world conferences. New disease-targeted medication has been developed such as endothelin receptor antagonists (bosentan, ambrisentan, sitaxentan, macitentan), prostacyclin derivates (inhaled and intravenous iloprost, epoprostenol, treprostinil), phosphodiesterase-5-inhibitors (sildenafil, tadalafil) and the soluble guanylate cyclase inhibitor riociguat. Despite these advances in treatment, the disease may not be treated causally or even be cured. In most cases however, disease progression may be slowed down. The use of PH-targeted treatment and supporting therapies such as anticoagulation and diuretics improve the symptoms and impede the progression of the disease. Nevertheless, the prognosis of the patients remains impaired. The first randomized controlled study investigating the effect of exercise training in PH showed a significant improvement of exercise capacity and quality of life. Further uncontrolled trials using a low-dose exercise and respiratory therapy in different etiologies of PH showed an improvement in exercise capacity, quality of life, muscle function and further prognostic parameters. A recent randomized controlled study could support these findings. Studies also showed an improvement in muscle capillarization of the quadriceps muscle.

The training program consists of interval ergometer training, respiratory therapy, muscle training and mental gait training. The interval ergometer training allows performing aerobic exercise training with a low cardio-circulatory stress. In patients with left heart insufficiency, this training has been successfully implemented. Respiratory therapy has been established in the rehabilitation of patients with lung disease within the last years. The different techniques aim to improve ventilation, strengthen the respiratory muscles, mobilize the thorax and enhance secretolysis. The training program also contains mental (gait) training. This training was adapted from mental imagery techniques used by sport psychologists in professional athletes. Mental imagery techniques have shown to improve physical and cognitive functions.

Due to the beneficial results, exercise training and rehabilitation has received a 1A recommendation at the PH world symposium in Nice in 2013. This decision was mainly based on three randomized controlled trials that investigated a limited number of patients. To unequivocally demonstrate safety and positive effects of exercise training in different settings large multicenter RCTs are essential. An exercise program has not yet been implemented in most European countries, partly due to limited access to rehabilitation programs and institutions.

The aim of this large, multicenter, prospective, randomized controlled trial is to investigate the effect of exercise training and rehabilitation on physical exercise capacity across different European countries. Physical exercise capacity will be measured by exercise induced change of 6-minute walking distance (6-MWD) compared to baseline and the control group without training. As inpatient settings are not available in all healthcare systems the training program will be adapted from the specific training program for PH patients developed in Heidelberg in a system, which is feasible for the local participating centres. Another objective of this study is to assess if the adopted training program specified for each participating centre and country is still safe and effective.

Tipo de estudo

Intervencional

Inscrição (Real)

129

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Heidelberg, Alemanha, 69126
        • Centre for pulmonary hypertension of the Thoraxclinic at the University Hospital Heidelberg

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Female and male patients of any ethnic origin ≥ 18 years
  • WHO functional class II-IV
  • PH diagnosed by right heart catheter showing:

    • Baseline mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg
    • Baseline pulmonary vascular resistance (PVR) ≥ 240 dyn x s x cm-5
    • Baseline pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg
  • Patients receiving optimized conventional PH therapy including intensified treatment with diuretics and who have been stable for 2 months before entering the study
  • Except for diuretics, medical treatment should not be expected to change during the entire 15-week study period
  • Negative pregnancy test (β-HCG) at the start of the trial and appropriate contraception throughout the study for women with child-bearing potential
  • Able to understand and willing to sign the Informed Consent Form

Exclusion Criteria:

  • PH of any cause other than permitted in the entry criteria, e.g. concomitantly to portal hypertension, complex congenital heart disease, reversed shunt, HIV infection, suspected pulmonary veno-occlusive disease based on pulmonary edema during a previous vasoreactivity test or on abnormal findings compatible with that diagnosis (septal lines or pulmonary edema at high resolution computer tomography), congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension or unclear diagnosis
  • Pregnancy
  • Patients with signs of right heart decompensation
  • Walking disability
  • Acute infection
  • Pyrexia
  • Any change in disease-targeted therapy within the last 2 months
  • Any subject who is scheduled to receive an investigational drug during the course of this study
  • Severe lung disease: FEV1/FVC <0.5 and total lung capacity < 70% of the normal value
  • Active liver disease, porphyria or elevations of serum transaminases >3 x ULN (upper limit of normal) or bilirubin > 1.5 x ULN
  • Hemoglobin concentration of less than 75 % of the lower limit of normal
  • Systolic blood pressure < 85 mmHg
  • Active myocarditis, instable angina pectoris, exercise induced ventricular arrhythmias, decompensated heart failure, hypertrophic obstructive cardiomyopathy, highly impaired left ventricular function
  • History or suspicion of inability to cooperate adequately. will be excluded from the study.

Additional exclusion criteria for MRI (optional)

  • Acute psychosis or other states of mind, which seem to impair patient's ability to comprehend instructions
  • Patients with metal cardiac valves or other metal implants, incorporated ferromagnetic materials or MRI-incompatible active medicinal products
  • Claustrophobia

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Diagnóstico
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Sem intervenção: Control group
Patients in this group continue their sedentary life-style throughout the study period. Patients will be advised to perform no specific exercise training during the trial. After 15 weeks, the patients are offered to take part in the training program as well.
Experimental: Training group

Standard rehabilitation therapy includes dietary measures, massages and relaxation techniques. Additionally, patients perform exercise and respiratory therapy and mental gait training.

Patients will be informed about group allocation.

The rehabilitation program comprises interval ergometer training, dumbbell training, respiratory therapy, mental training and guided walks for 5-7 times/week.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
6 MWD
Prazo: 15 weeks
Change in 6-MWD between baseline and 15 weeks in the training vs. the control Group; meters
15 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in WHO functional class in training vs. control group
Prazo: 15 weeks
WHO functional class
15 weeks
Change in Quality of life in training vs. control group
Prazo: 15 weeks
Quality of life (SF-36)
15 weeks
Change in Borg scale 6-MWD training vs. control group
Prazo: 15 weeks
Borg scale 6-MWD
15 weeks
Change in tricuspid annular plane systolic excursion
Prazo: 15 weeks
Echocardiographic parameter training vs. control Group; mm
15 weeks
Change in tissue Doppler imaging
Prazo: 15 weeks
Echocardiographic Parameter training vs. control group
15 weeks
Change in left ventricular pump function
Prazo: 15 weeks
Echocardiographic Parameter training vs. control Group; qualitative
15 weeks
Change in right ventricular pump function
Prazo: 15 weeks
Echocardiographic Parameter training vs. control Group; qualitative
15 weeks
Change in thickness of interventricular septum
Prazo: 15 weeks
Echocardiographic Parameter training vs. control Group; mm
15 weeks
Change insize of inferior vena cava
Prazo: 15 weeks
Echocardiographic Parameter training vs. control Group; mm
15 weeks
Change in systolic pulmonary arterial pressure
Prazo: 15 weeks
Echocardiographic Parameter training vs. control Group; mmHg
15 weeks
Change in left ventricular eccentricity index
Prazo: 15 weeks
Echocardiographic Parameter training vs. control group
15 weeks
Change in Tei index
Prazo: 15 weeks
Echocardiographic Parameter training vs. control group
15 weeks
Change in right ventricular area
Prazo: 15 weeks
Echocardiographic Parameter training vs. control group
15 weeks
Change in right atrial area
Prazo: 15 weeks
Echocardiographic Parameter training vs. control Group; square cm
15 weeks
Change in workload
Prazo: 15 weeks
Cardiopulmonary exercise testing (spiroergometry) training vs. control Group; Watts
15 weeks
Change in heart rate
Prazo: 15 weeks
Cardiopulmonary exercise testing (spiroergometry) training vs. control Group; bpm
15 weeks
Change in ventilation
Prazo: 15 weeks
Cardiopulmonary exercise testing (spiroergometry) training vs. control Group; L/min
15 weeks
Change in carbon dioxide output
Prazo: 15 weeks
Cardiopulmonary exercise testing (spiroergometry) training vs. control Group
15 weeks
Change in spiroergometry parameters in training vs. control group
Prazo: 15 weeks
Cardiopulmonary exercise testing (spiroergometry): VO2 at anaerobic threshold determined by V-slope method
15 weeks
Change in VCO2 at anaerobic threshold
Prazo: 15 weeks
Cardiopulmonary exercise testing (spiroergometry): determined by V-slope method
15 weeks
Change in oxygen uptake
Prazo: 15 weeks
Cardiopulmonary exercise testing (spiroergometry); L/min/kg
15 weeks
Change in diffusion-limited carbon monoxide (DLCO)
Prazo: 15 weeks
Lung function; Diffusion capacity
15 weeks
Change in alveolar volume (VA)
Prazo: 15 weeks
Lung function
15 weeks
Change in residual volume (RV)
Prazo: 15 weeks
Lung function
15 weeks
Change in total lung volume (TLC)
Prazo: 15 weeks
Lung function
15 weeks
Change in forced expiratory flow
Prazo: 15 weeks
Lung function
15 weeks
Change in peak expiratory flow rate
Prazo: 15 weeks
Lung function
15 weeks
Change in forced expiratory volume in one second (FEV1)
Prazo: 15 weeks
Lung function; total and in percentage
15 weeks
Change in forced vital capacity (FVC)
Prazo: 15 weeks
Lung function
15 weeks
Change in NTproBNP
Prazo: 15 weeks
Laboratory marker for the impairment of the right heart
15 weeks
Change in interleukins
Prazo: 15 weeks
Laboratory marker for the impairment of the right heart
15 weeks
Change in inflammatory markers
Prazo: 15 weeks
Laboratory marker for the impairment of the right heart
15 weeks
Change in carbon dioxide partial pressure
Prazo: 15 weeks
Blood gas Analysis
15 weeks
Change in oxygen saturation of the blood (SaO2)
Prazo: 15 weeks
Blood gas analysis
15 weeks
Change in additional oxygen supplementation (yes/no and quantity)
Prazo: 15 weeks
Blood gas analysis
15 weeks
Change in oxygen partial pressure
Prazo: 15 weeks
Blood gas analysis
15 weeks
Change in oxygen saturation
Prazo: 15 weeks
Safety Parameter; L/min
15 weeks
Assessment of clinical laboratory Investigation alerts (values out of range)
Prazo: 15 weeks
Safety parameter
15 weeks
Assessment of adverse Events
Prazo: 15 weeks
Safety Parameter; unrelated and related to procedure
15 weeks
Assessment of serious adverse events
Prazo: 15 weeks
Safety parameter
15 weeks
frequency of hospitalizations
Prazo: 15 weeks
Safety parameter
15 weeks
length of hospitalizations
Prazo: 15 weeks
Safety parameter
15 weeks
Change in resting heart rate
Prazo: 15 weeks
Safety parameter
15 weeks
Change in blood pressure
Prazo: 15 weeks
Safety parameter
15 weeks
frequency of pathological findings in long-term ECG
Prazo: 15 weeks
Safety parameter
15 weeks
Qualitative Review of electrocardiogram (ECG)
Prazo: 15 weeks
Safety Parameter; pathological findings
15 weeks
Assessment of survival
Prazo: 1 year
Training and control Group; transplant-free and Overall survival
1 year
Change of the right ventricular size
Prazo: 15 weeks
Optional: Changes in MRI parameters
15 weeks
Change of the right ventricular pump function
Prazo: 15 weeks
Optional: Changes in MRI parameters
15 weeks
Change of the left ventricular size
Prazo: 15 weeks
Optional: Changes in MRI parameters
15 weeks
Change of the left ventricular pump function
Prazo: 15 weeks
Optional: Changes in MRI parameters
15 weeks
Change in microRNA expression
Prazo: 15 weeks
Optional: Epigenetic changes
15 weeks
Change in DNA-methylation
Prazo: 15 weeks
Optional: Epigenetic changes
15 weeks
Assessment of relationship of DNA mutations and disease progression
Prazo: 15 weeks
Optional: Investigation of DNA mutations relationship to disease progression
15 weeks
Assessment of relationship of DNA mutations and training effects
Prazo: 15 weeks
Optional: Investigation of DNA mutations
15 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Ekkehard Grünig, MD, Centre for pulmonary hypertension of the Thoraxclinic at the University Hospital Heidelberg

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de fevereiro de 2016

Conclusão Primária (Real)

1 de dezembro de 2018

Conclusão do estudo (Real)

1 de dezembro de 2019

Datas de inscrição no estudo

Enviado pela primeira vez

27 de julho de 2017

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de novembro de 2017

Primeira postagem (Real)

17 de novembro de 2017

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de dezembro de 2019

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de dezembro de 2019

Última verificação

1 de dezembro de 2019

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • EU-TRAIN-01

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever